期刊
JOURNAL OF NEUROIMMUNOLOGY
卷 232, 期 1-2, 页码 136-144出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jneuroim.2010.10.031
关键词
Glatiramer acetate; Inflammation; B cells; CD19; CD5
资金
- Teva Pharmaceuticals, LTD, Petah Tiqva, Israel [R01 AI061938 - NIAID]
- National Multiple Sclerosis Society [CA1027A1/3]
We recently showed that B cells reduce CNS inflammation in mice with experimental allergic encephalomyelitis (EAE). Here, we demonstrate that adoptively transferred CD5/CD19+ B cells protect against EAE severity. Furthermore, we show that glatiramer acetate (GA), a therapeutic for relapsing multiple sclerosis treatment, amplifies this effect. Transfer of GA-conditioned B cells leads to increased production of immunoregulatory cytokines and reduced CNS inflammation, as well as decreased expression of the chemokine receptor, CXCR5, and elevated BDNF expression in the CNS. Thus B cells can protect against EAE, and GA augments this effect in maintaining immune homeostasis and controlling EAE disease progression. (C) 2010 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据